AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA
Active, not recruiting
- Conditions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT06422676
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT06422689
- Locations
- 🇺🇸
Research Site, Greenville, North Carolina, United States
A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
Active, not recruiting
- Conditions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06422663
- Locations
- 🇨🇳
Research Site, Zigong, China
A Non-interventional, Prospective Study With Benralizumab
Recruiting
- Conditions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06422078
- Locations
- 🇩🇪
Research Site, Wurzburg, Germany
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
Recruiting
- Conditions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06419413
- Locations
- 🇨🇳
Research Site, Zhaoqing, China
FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage
Recruiting
- Conditions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT06420011
- Locations
- 🇦🇪
Research Site, Al Ain, United Arab Emirates
Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.
Recruiting
- Conditions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT06417801
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06414746
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT06406400
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath